Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)

BACKGROUND: Apatinib was shown to improve the survival of Chinese patients with refractory metastatic gastric cancer (mGC). As an orally administered drug, it has been widely used in elderly patients because the dosing schedule can be adjusted flexibly. However, data on the efficacy and safety of ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiang, Zhong, Diansheng, Zhang, Junping, Du, Nan, Ren, Yuchuan, Gao, Jinghua, Liu, Likun, Yu, Junyan, Li, Xiaomei, Ma, Liwen, Zang, Aimin, Yang, Mudan, Zhang, Yan, Guo, Jun, Liu, Zheng, Fu, Zhanzhao, Jia, Junmei, Diao, Jianfeng, Fan, Zaiwen, Song, Xiang, Li, Guozhong, Wang, Huaqing, Bai, Chunmei, Guan, Mei, Ren, Xiubao, Zhang, Ruixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459208/
https://www.ncbi.nlm.nih.gov/pubmed/36092345
http://dx.doi.org/10.21037/jgo-22-727
Descripción
Sumario:BACKGROUND: Apatinib was shown to improve the survival of Chinese patients with refractory metastatic gastric cancer (mGC). As an orally administered drug, it has been widely used in elderly patients because the dosing schedule can be adjusted flexibly. However, data on the efficacy and safety of apatinib in elderly patients is scarce. The aim of this study was to evaluate the toxicity and effectiveness of apatinib for elderly patients with mGC in a real-world setting. METHODS: Data from the sub-population of patients who were ≥65 years enrolled in the AHEAD-G202 trial were analyzed. Patients with mGC were prospectively registered and initially received ≤850 mg oral apatinib daily combined or not combined with chemotherapy, at the investigator’s discretion. The primary endpoint was safety. The secondary endpoints were overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 117 patients were included. There were 51 (43.59%) patients in the low-dose (250 mg) group, 60 (51.28%) patients in the mid-dose (425 to 500 mg) group, and 6 (5.13%) patients in the high-dose (850 mg) group according to the initial daily doses. Hypertension (6.84%) was the only grade 3–4 adverse event (AE) with a prevalence of more than 5% and across the low-dose (11.76%), mid-dose (3.33%) and high-dose group (0%). The median OS and PFS were 7.13 months (95% CI: 5.04 to 9.22 months) and 4.27 months (95% CI: 3.24 to 5.29 months), respectively. The OS and PFS were similar among the 65–74 and ≥75 years groups (χ(2)=1.406, P=0.306; χ(2)=0.378, P=0.066, respectively). The OS and PFS were also comparable among the 3 dose groups. CONCLUSIONS: Elderly patients with mGC can tolerate and benefit from apatinib therapy. A lower initial daily dosing strategy may be a suitable choice for elderly patients in clinical practice.

Ejemplares similares